Can Adagrasib be used in combination with other targeted drugs?

Adagrasib is a KRAS G12C inhibitor, specifically used to treat patients with non-small cell lung cancer (NSCLC) and other solid tumors carrying KRAS G12C mutations. As a target of KRAS G12C, a mutation site that was once considered "undruggable", the emergence of adagrasib has brought new treatment hope to these patients. Like other targeted drugs, although its monotherapy effect is clear, there are also drug resistance problems, which has promoted the exploration of combination treatment options.

Currently, research on the combined use of adagrasib with other targeted drugs is being actively promoted. Especially in the field of non-small cell lung cancer, combination therapy with targeted drugs related to EGFR, MET or SH2 domains has become a research hotspot. This type of combination aims to block multiple tumor-driving pathways at the same time, thereby enhancing the anti-tumor effect and delaying or overcoming the occurrence of drug resistance. For example, the combination of adagrasib and MET inhibitors has shown synergistic anti-cancer effects in preclinical experiments and has entered the early clinical research stage.

In addition, in colorectal cancer and other KRAS G12C mutated solid tumors, adagrasib is also being tried for combined treatment with EGFR monoclonal antibodies (such as cetuximab). Early trials show that this combination strategy has certain advantages in controlling tumor progression, especially in patients with limited efficacy of single agent. However, the long-term safety and optimal dosage regimen of such combinations still need to be further verified through clinical trials.

To sum up, adagrasib has the potential to be used in combination with other targeted drugs, especially in clinical situations where drug resistance or single drugs are ineffective. However, this type of combination therapy is still in the clinical trial stage, and a unified treatment standard has not yet been formed. If patients consider combining medications, they must do so under the guidance of a professional doctor to ensure both efficacy and safety.

References：https://www.krazati.com/